Evidence Hub

Decisions to withdraw or withhold life-sustaining therapies in patients with and without acute brain injury: a secondary analysis of two prospective cohort studies

Shaurya Taran, Kuan Liu, V. McCredie, Ó. Peñuelas, Karen E. A. Burns, F. Frutos-Vivar, Damon C. Scales, Niall D. Ferguson et al.

The Lancet Respiratory Medicine, 2025

21 participants · 12 citations

Abstract

BACKGROUND

Many deaths in the intensive care unit (ICU) occur after a decision to withdraw or withhold life-sustaining therapies (WLSTs). We aimed to explore the differences in the incidence and timing of WLST between patients with and without acute brain injuries (ABIs).

METHODS

We did a secondary analysis of two prospective, international studies that recruited patients who were invasively or non-invasively ventilated between 2004 and 2016 from 40 countries. ABI was defined as brain trauma, ischaemic stroke, intracranial haemorrhage, seizures, or meningitis-encephalitis. The comparator group included non-ABI conditions. Time to WLST was evaluated by use of cumulative incidence curves. Differences in WLST were analysed by use of multilevel logistic regression.

FINDINGS

Between March 11, 2004, and Dec 17, 2016, we recruited 21 970 patients (16 791 in the WLST analysis), of whom 13 526 (61·6%) were male and 8444 (38·4%) were female and 2896 (13·2%) had ABI. WLST occurred in 2056 (12·2%) of 16 791 patients) and was more common in patients with ABI versus without (372 [17·0%] of 2191 vs 1684 [11·5%] of 14 600; risk difference 5·5%; 95% CI 3·8-7·1; odds ratio [OR] 2·42; 1·89-3·12). WLST decisions occurred earlier in patients with ABI versus patients without ABI (median, 4 days [IQR 2-9] versus 6 days [2-13] after ICU admission; absolute difference, 2 days; 95% CI 1-3). Findings were similar across different ABI subgroups, world regions, and cohort years. Variability among ICUs…

How strong is the evidence?

Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 21 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free